Acetoxymethylketobemidone

Acetoxymethylketobemidone (O-AMKD), is an opioid designer drug related to ketobemidone, with around the same potency as morphine. It was first identified in Germany in October 2020.[1][2]

Acetoxymethylketobemidone
Identifiers
  • [3-(4-acetyl-1-methylpiperidin-4-yl)phenyl] acetate
CAS Number
PubChem CID
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H21NO3
Molar mass275.348 g·mol−1
3D model (JSmol)
  • CC(=O)C1(CCN(CC1)C)C2=CC(=CC=C2)OC(=O)C
  • InChI=1S/C16H21NO3/c1-12(18)16(7-9-17(3)10-8-16)14-5-4-6-15(11-14)20-13(2)19/h4-6,11H,7-10H2,1-3H3
  • Key:ZXPASXBVYVTLRG-UHFFFAOYSA-N

See also

edit

References

edit
  1. ^ European Monitoring Center for Drugs and Drug Addiction (December 2020). "New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic" (PDF). An Update from the EU Early Warning System. Luxembourg: Publications Office of the European Union. doi:10.2810/921262. ISBN 9789294975584.
  2. ^ Lamy FR, Daniulaityte R, Barratt MJ, Lokala U, Sheth A, Carlson RG (August 2021). ""Etazene, safer than heroin and fentanyl": Non-fentanyl novel synthetic opioid listings on one darknet market". Drug and Alcohol Dependence. 225: 108790. doi:10.1016/j.drugalcdep.2021.108790. PMID 34091156. S2CID 235362241.